$TRAX News

HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $57 Price Target

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

Barclays Maintains Overweight on First Tracks, Raises Price Target to $65

First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results

Wedbush Maintains Outperform on First Tracks, Raises Price Target to $70

Piper Sandler Maintains Overweight on First Tracks, Raises Price Target to $95

HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $57

First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update

First Tracks Q2 EPS $(0.95) Up From $(1.47) YoY

UBS Maintains Buy on First Tracks, Raises Price Target to $65

Wedbush Maintains Outperform on First Tracks, Raises Price Target to $60

Wells Fargo Maintains Overweight on First Tracks, Raises Price Target to $55

Barclays Maintains Overweight on First Tracks, Raises Price Target to $48

HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $44

HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $30 Price Target

Wells Fargo Initiates Coverage On First Tracks with Overweight Rating, Announces Price Target of $30

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome